Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2150
Abstract: Purpose: Polyclonal emergence of KIT secondary mutations is a main mechanism of imatinib progression in gastrointestinal stromal tumor (GIST). Approved KIT inhibitors sunitinib and regorafenib have complementary activity against KIT resistance mutations. Preclinical evidence suggests… read more here.
Keywords: rapid alternation; treatment; sunitinib regorafenib; gastrointestinal stromal ... See more keywords
Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.11038
Abstract: 11038Background: We retrospectively collected data from metastatic Italian GIST patients treated with imatinib or sunitinib reintroduction after progression to conventional three or four lines of t... read more here.
Keywords: sunitinib regorafenib; imatinib sunitinib; advanced gist; gist progressing ... See more keywords
Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.11510
Abstract: 11510Background: Polyclonal emergence of KIT secondary mutations (muts) is the main mechanism of imatinib (IM) progression in GIST. Although approved KIT inhibitors SU and RE each suppress only a s... read more here.
Keywords: rapid alternation; alternation sunitinib; study rapid; gist ... See more keywords